|
A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients Clinical research trials and A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients. A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients clinical trial. Subjects frequently obtain the most expert healthcare possible for their A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients  A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients
A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients
For Condition: HIV Infections
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: The purpose of this study is to see if it is safe and effective to add 141W94 to an anti-HIV regimen that includes retrovir plus epivir.
Details: This is a double-blind, placebo-controlled, two-arm study comparing treatment with a triple regimen consisting of 141W94, retrovir, and epivir and a double regimen consisting of retrovir and epivir.
Eligibility:
Study Type: Interventional, Treatment, Parallel Assignment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: - HIV-positive status. - Screening viral load >= 10,000 copies/mm3 14 days prior to entry. - CD4+ cell counts >= 200 cells/mm3 14 days prior to entry. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Clinical diagnosis of AIDS (CDC 1993 Classification C). Concurrent Medication: Excluded: Terfenadine, astemizole, cisapride, triazolam, medazolam, and ergotamine/dihydroergotamine-containing regimens. Patients with the following prior conditions are excluded: Clinically relevant hepatitis in the previous 6 months. Prior Medication: Excluded: - Greater than 4 weeks of any nucleoside antiretroviral therapy. - Previous therapy with an HIV protease inhibitor. - Cytotoxic chemotherapeutic agents within 4 weeks prior to entry. - Immunomodulating agents within 3 months prior to entry. Prior Treatment: Excluded: Radiotherapy within 4 weeks prior to entry. Risk Behavior: Excluded: Current alcohol or illicit drug use that may interfere with the patient's ability to comply with the dosing schedule or protocol evaluations.
Total Enrollment: 290
Location and Contact Information:
Community Research Initiative of Central Florida
Maitland, Florida, 32751
United States
Univ of Miami School of Medicine
Miami, Florida, 33136
United States
Dr Bruce Rashbaum
Washington D.C., District of Columbia, 20037
United States
Community Research Initiative of New England
Brookline, Massachusetts, 02445
United States
Community Research Initiative of South Florida
Coral Gables, Florida, 33146
United States
Chicago Ctr for Clinical Research
Chicago, Illinois, 60610
United States
Methodist Hosp
Memphis, Tennessee, 38104
United States
Saint Vincent's AIDS Ctr
New York City, New York, 10011
United States
Pacific Oaks Research
Beverly Hills, California, 90211
United States
Additional Information:
Study ID Numbers: 264D; PROA3001
Study Start Date:
Record last reviewed: November 1998
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002195
Other Hiv Infections Studies:
1. A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination with QS21 Adjuvant or Alum in Healthy Adults
2. Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir
3. A Study to Compare Three Doses of T-20 When Given in Combination with Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults
4. A Comparison of HIV-Infected Patients with and without Opportunistic (AIDS-Related) Infection
5. The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment
Related Studies:
Other HIV Infections Clinical Trials
Other Florida Clinical Trials
Other Coral Gables Clinical Trials
A Study of Retrovir and Epivir Alone or in Combination with 141W94 in HIV-Infected Patients
|
|
|
|
|
|
|
|
